BLDR vs LTM

The company exhibits strong financial health with a Piotroski F-Score of 7/9, indicating solid operational and balance sheet fundamentals. However, despite this strength, the business is facing significant near-term headwinds, evidenced by sharp year-over-year declines in revenue (-6.9%) and earnings (-54.9%), which are weighing on performance. Valuation metrics suggest the stock is trading at a premium to both Graham’s defensive value ($67.26) and growth-based intrinsic value ($36.05), though below the sector’s elevated average P/E. Analysts maintain a 'buy' recommendation with a $131.00 target, implying upside potential if macro or operational conditions improve.

LTM presents a stark contrast between explosive growth and precarious financial health, evidenced by a stable but mediocre Piotroski F-Score of 4/9. While the company boasts an impressive 87.5% YoY earnings growth and a low P/E of 9.48, its balance sheet is severely stressed with a Debt/Equity ratio of 6.05 and a Current Ratio of 0.60. The stock trades at a significant premium to its Graham Number ($21.11) but remains well below its growth-based intrinsic value ($146.03). Despite a 'strong_buy' analyst consensus, the 0/100 technical trend and poor liquidity metrics necessitate a neutral stance.